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With rising incidence and emergence of eﬀective treatment options, the management of hepatocellular carcinoma (HCC) is
a complex multidisciplinary process. There is still little consensus and uniformity about clinicopathological staging systems.
Resection and liver transplantation have been the cornerstone of curative surgical treatments with recent emergence of ablative
techniques. Improvements in diagnostics, surgical techniques, and postoperative care have lead to dramatically improved results
over the years. The most appropriate treatment plan has to be individualised and depends on a variety of patient and tumour-
related factors. Very small HCCs discovered on surveillance have the best outcomes. Patients with advanced cirrhosis and tumours
within Milan criteria should be oﬀered transplantation. Resection is best for small solitary tumours with preserved liver function.
Ablative techniques are suitable for low volume tumours in patients unﬁt for either resection or transplantation. The role of
downstaging and bridging therapy is not clearly established.
1.Introduction
Hepatocellular carcinoma (HCC) is the ﬁfth commonest
cancer in the world in men and is the third highest con-
tributor towards any cancer-related mortality [1]. Although
the highest number of cases relates to the Far East, Middle-
East, and Africa, the last decades have seen nearly a doubling
of the incidence of HCC in the western world, particularly
in the United States with the trend still on the rise [2].
The vast majority of HCCs occur on a background of pre-
existing liver disease, and more recently, Hepatitis C (HCV)
and nonalcoholic steatohepatitis (NASH) have emerged as
the leading causes of cirrhosis and thereby, HCC.
Unfortunately, late presentation is all too common, and a
recent analysis of the SEER (Surveillance, Epidemiology and
EndResult)databaserevealedthatjustabout16%ofpatients
were suitable for some kind of surgical therapy in the form of
resection, transplantation, or ablation [3]. However, surgical
and ablative modalities oﬀer the only possibility of long-
termcure.Surgicaltreatmentoptionsdependnotonlyonthe
extent of the cancer but also on the status of the liver and the
generalconditionofthepatient. Intheory,thebest outcomes
should be obtained in patients with well-compensated liver
diseasewithoutsevereportalhypertension,whoaregenerally
in good health and have a small tumour burden. Hence
surveillance programmes have been established, particularly
in high-risk geographical areas, for the early detection
of HCCs to facilitate curative treatment and improved
outcomes [4]. This paper discusses the improving outcomes
associated with surgical management of HCC.
2. Stagingof HCC
Clinical management of HCC is a multidisciplinary process
involving hepatologists, surgeons, oncologists, and radiol-
ogists. Staging is an integral part of the decision-making
process so that treatment can be individualised. Since the
vastmajority ofHCCs occuronabackgroundofliverdisease
with or without cirrhosis, it is clear that prognosis does
not depend exclusively on tumour-related factors but also
on liver function, general health, and other comorbidities
of the patient and response to various medical treatments
depending on the aetiology [5]. Staging of HCC is diﬃcult,
and a wide variety of systems have been in existence for2 International Journal of Hepatology
years. They include those that deal exclusively with tumour
staging pre- and postoperatively, pathological staging of the
resected tumour, general staging for liver disease, and those
that were initially developed to predict factors determining
outcome of liver disease with or without HCC. However,
only three of them have been validated in patient cohorts
[6].Thedetaileddescription andanalysisofthesearebeyond
the scope of this paper. The current consensus is that no
single staging system is universally applicable and there is
signiﬁcant heterogeneity in patient groups even within the
same stage, particularly since the aetiology and prognosis of
liverdiseasearemultifold [7].T umoursi z ealo n ei sani n c o n -
sistent determining factor, yet transplant criteria are based
predominantlyonsize.Histologicalcharacteristicswhichcan
potentially prognosticate outcome cannot unfortunately be
determined preoperatively. Some uniformity in staging is
essential, and the various diagnostic tools used to stage and
assess HCC pretreatment need to be standardised.
The BCLC (Barcelona Clinic Liver Cancer) staging,
which has been recently updated, attempts to match stag-
ing with both prognosis and treatment options, thereby
developing an evidence-based algorithm for the surgical
and medical management of HCC [8]. This has not gained
universal acceptance and is probably popular mainly in
the European countries. Other geographical study groups
have also published consensus recommendations. The Asian
Paciﬁc Association for the Study of Liver (APASL) convened
an international working party to develop consensus recom-
mendations for the diagnosis, surveillance, and management
of HCC. A treatment algorithm was proposed, which, again,
takes into account resectability and size of the HCC and the
general condition of the patient [9]. Finally, the National
Comprehensive Cancer Network (NCCN) has published
and updated clinical practice guidelines for hepatobiliary
oncology with a treatment algorithm for the diagnosis and
management of HCC which, similar to the APASL, is based
on resectability, status of liver disease, and general condition
[10]. Unlike the BCLC, neither speciﬁcally makes an attempt
to formally classify HCC into stages. It should, however, be
noted that both the APASL and the NCCN are consensus
guidelines derived from evidence-base and large panels of
international experts rather than a single-centre approach.
Individual aspects of these algorithms are discussed further
in the paper.
3. SurgicalModalitiesfor
the Management of HCC
3.1. Liver Transplantation. Liver transplantation (LT) has
been used to treat HCC with cirrhosis for nearly three
decades. It is the only surgical treatment which simulta-
neously addresses the liver condition and, essentially, cures
two related problems. Early results of LT for HCC were
disappointing. In absence of speciﬁc inclusion criteria, many
patients with HCC were transplanted for advanced disease
resulting in an overall poor survival [11–13]. For LT to
be universally acceptable as a treatment option for HCC,
it not only had to demonstrate better results than other
treatment options but also to achieve at least 50% survival
at 5 years to justify use of scarce donor organs. Therefore,
it was necessary that certain criteria are used to preselect
patients suitable for transplantation. Increasing tumour size
and bulk, vascular invasion, extrahepatic nodal disease, and
worse tumour histology were long known to be indicators of
poor prognosis with other treatment modalities. Prognosis
after transplantation for HCC was also noted to be better
in early stage disease. It was only in 1996 that Mazzaferro
et al. in a prospective study clearly deﬁned inclusion criteria
(single tumour <5cm or 1–3 tumours, none >3cm)which
showed a signiﬁcant survival beneﬁt [14]. Since then, the
so-called “Milan criteria” have gained universal acceptance,
and the results have been replicated in other studies [15, 16].
ThesehavelongbeenadoptedbyUNOS(Unitednetworkfor
organ sharing) as the optimal criteria for LT and in the TNM
staging. After the introduction of MELD score for organ
allocation, bonus “points” were awarded to early stage (T1
and T2) HCCs in an attempt not to disadvantage patients
with low-grade tumours and good synthetic liver function.
However, this led to an overcorrection and a signiﬁcant
increase in the number of patients transplanted for HCCs
at the expense of other indications. It was noted that the
dropout rate for T1 tumours in the pre-MELD era was under
10%, which is less than the overall waiting list mortality. This
has thus led to elimination of the score upgrading for T1
lesions and a lesser upgrade for T2 lesions [17, 18]. This has
not necessarily had an adverse impact on survival, and there
has been a signiﬁcant increase in the number of transplants
performed for early HCC in cirrhosis [19].
3.1.1. Results of Liver Transplantation for HCC. The original
Milan study reported 4-year and recurrence-free survival
rates of 75% and 83%, respectively, and their 10-year overall
survival is over 70% in transplants performed for HCC
within Milan criteria [20]. Similar results have been achieved
in other centres, and a 5-year survival of well over 70% has
been reported in patients undergoing LT for HCC within
Milan criteria [15, 16].
It has to be argued, however, that these are data from sin-
gle centres and may not accurately reﬂect the entire picture.
Any comparison between diﬀering treatment modalities has
to take into account an intention-to-treat analysis which, in
case of LT, is tempered by waiting times and waiting list
dropout and mortality which vary between 20% and 30%
[4]. It has been shown that mortality from the time of listing
for LT increases signiﬁcantly with increasing waiting times
[21]. Pooled registry data incorporating a very large number
of patients have clearly shown that the long-term survival
ﬁgures do not necessarily replicate data from the best single
centres.Ananalysisof4482patientswithintheUNOSOrgan
Procurement Transplant Network data demonstrated that
overall intention-to-treat 5-year survival after LT for HCC
was 61% even for those favourable group of patients within
Milan criteria [22]. This ﬁgure went up to 65% when only
patients who underwent LT were taken into account. Table 1
summarises outcomes after LT for HCC in major series.
Over the last decade, there has been a vigorous debate
over expansion of the Milan criteria. Proponents have
demonstrated outcomes comparable to those with MilanInternational Journal of Hepatology 3
Table 1: Results of liver transplantation for HCC.
Author Year Number of
patients
Inclusion
criteria if any
3-year survival
(%)
5-year survival
(%)
Iwatsuki et al. [11] 1991 105 None 47
Bismuth et al. [12] 1993 60 None 47
Ringe et al. [13] 1991 61 None 15.2
Mazzaferro et al. [14] 1996 48 Milan criteria 74 (4-year)
Jonas et al. [15] 2001 120 Milan 71
Figueras et al. [16] 2001 307 Milan 63
Yao et al. [23] 2001 70 USCF 75a
Onaca et al. [24] 2007 1206 Milan 62
Duﬀye ta l .[ 25] 2007 467 Milan
UCSF
79
64b
Pelletier et al. [22] 2009 2898 Milan 65c
Cescon et al. [29] 2010 283 Milan 75
UCSF: University of California San Francisco criteria (single tumour <6.5cm, 2-3 tumours, none >4.5cm and total tumour dimensions up to 8cm).
aSurvival for all patients within UCSF criteria.
bSurvival for patients beyond Milan but within UCSF criteria.
cIntention-to-treat survival: 61%.
Table 2: Results of liver transplantation for HCC beyond Milan criteria, based on preoperative imaging. (From national/large regional
studies.)
Author Year Number of
patients
5-year
survival (%) Notes
Decaens et al. [26] 2006 44
145
45.6
34.7
Beyond Milan, within UCSF
Beyond UCSF
Duﬀye ta l .[ 25] 2007 185
109
64
41
Beyond Milan, within UCSF
Beyond UCSF
Pelletier et al. [22] 2009 346 38
32
Beyond Milan
Intention-to-treat survival
criteria and argue that maintaining the restriction of criteria
would exclude patients that would otherwise do well after
transplantation despite a larger tumour burden [23–25].
Others equally insist that original criteria are strictly adhered
to in view of the inconsistent results achieved after trans-
planting patients with larger tumours, speciﬁcally arguing
that potential beneﬁciaries of expansion of criteria have
signiﬁcantly worse outcomes [26]. The UNOS data demon-
strated that the intention-to-treat 5-year survival for patients
listed LT for HCC beyond Milan criteria was only 32% and
38% for those patients that actually underwent LT [22].
Table 2 summarises results of these studies. Retrospective
designs of most studies and the impossibility of prospective
randomised controlled comparative studies between these
groups make direct comparisons unreliable. Also, there is
no deﬁnite consensus in terms of how further should these
criteria be expanded. Finally, ready acceptance to expand
the criteria is tempered by the two critical issues facing
the transplantation community: burgeoning waiting times
and increasing dropout rates and mortality due to tumour
progression and complications of underlying liver disease.
Hence, currently, Milan criteria still remain valid in most
transplant units.
3.1.2. Factors Determining Outcome after LT for HCC. There
is clear evidence that postoperative histology correlates
with disease recurrence and survival. Even in the group of
patients within Milan criteria, vascular invasion and tumour
undiﬀerentiationcarryworseprognosis[15,27].Othershave
demonstrated that variables, such as higher total tumour
burden, higher preoperative alpha-fetoprotein, and presence
of tumour necrosis, predict signiﬁcantly worse outcomes
[28, 29]. It has been discussed that survival of patients
beyond Milan but within UCSF criteria is worse thereby
suggesting that tumour size may indeed be a surrogate
marker of adverse histological features such as vascular inva-
sion, the one criterion consistently shown to predict worse
survival.
3.1.3. Living Donor Liver Transplantation (LDLT) for HCC.
DropoutrateforHCCisrelatedbothtowaitinglistmortality
in patients with advanced liver disease per se and to tumour
progression beyond Milan criteria despite preserved liver
function. LDLT could potentially beneﬁt such patients who
would otherwise be rendered nontransplantable. It could
also cater for the 10–20% patients with HCC beyond
Milan but within UCSF criteria without having an impact4 International Journal of Hepatology
on the availability and distribution of organs across the
program. Patient survival and disease-free survival after
LDLT for HCC are comparable to cadaveric transplantation.
As with other series, tumour size, histological grade, vascular
permeation, preoperative serum alpha-fetoprotein, and pre-
operative MELD score correlated with survival and disease
recurrence. Survival was worse in patients beyond Milan
criteria[30,31].Inanotherstudy,LDLThadpooreroutcome
compared to cadaveric transplantation in patients with large
HCCs [32]. Although it was not statistically signiﬁcant, the
2-year patient survival was 60%. Long-term outcomes were
not reported.
The ethical issues with LDLT and, in particular, the
potential dangers to a healthy adult have been long debated.
There is small but signiﬁcant risk mortality to the donor.
Signiﬁcant morbidity occurs in about 20% of donors, and
up to 50% experience various minor complications [33].
Postoperative biliary and vascular complications are higher
in the recipient. The projected patient and graft survival
rates are potentially lower in view of these complications and
LDLTbeingusedformoreadvanceddisease.HCV-associated
cirrhosis, which is frequently associated with HCC, carries
a worse prognosis, and there is evidence that recurrence is
more severe after LDLT [34]. There is a danger that if LDLT
is advocated for tumours beyond Milan criteria, there would
be a pressure on the patient to ﬁnd a suitable living donor
and on the donor to fulﬁl an obligation for a potentially
nonbeneﬁcial cause. Altruistic donation, too, could come
under close scrutiny if used for such indications. However,
HCC represents a good indication for LDLT. The majority
of patients listed for LT do not have advanced liver disease
and would have a much better prognosis than patients
transplanted for end-stage liver disease.
Families involved in LDLT need to be given clear advice,
and their wishes need to be taken into consideration. Since
LDLT does not primarily tap into cadaveric organ pool,
even a slightly low survival should be considered acceptable
since the outcome would be signiﬁcantly better than other
treatment modalities. However, in the event of graft failure
in a patient transplanted for HCC exceeding current criteria,
it would be highly contentious to turn to retransplantation
with a cadaveric organ, and this issue has to be clearly
discussed with the family. Thus LDLT has an important role
to ﬁll in LT for HCC.
3.2. Surgical Resection. Surgical resection for HCC was the
only modality for curative treatment before the routine use
of LT and has several practical advantages over it. Firstly,
there are no restrictions on tumour size and numbers as long
as resection can be safely performed. Secondly, resections
can be performed in any nontransplant setup that has an
adequate radiological and medical backup. Finally, it does
not rely on a donor pool, and there are no waiting times
for treatment. However, there are distinct disadvantages.
Resection does not address and cure the background liver
disease,therebyretainingafertilebackgroundforrecurrence.
Secondly, it compromises an already damaged liver by
removing vital functioning liver mass and is reliant on a
well functioning liver with adequate reserves. Finally, in the
event of liver decompensation and failure, emergency liver
transplantation as a rescue treatment may not be available,
particularly if the Milan criteria in the resected specimen
have been exceeded or if poor prognostic features are evident
on histology.
3.2.1. Results for Liver Resection for HCC. The key factor
that determines outcomes is patient selection. As mentioned
before, although tumour bulk need not necessarily present
restriction, liver function and extent of the background
liver disease do. Just as early results with LT for HCC were
disappointing, so were results with resection, and the best
5-year survival rates in the 1980s were about 32% [35].
These ﬁgures were signiﬁcantly improved upon in the later
decades with large Eastern studies demonstrating a 5-year
survival of nearly 50% in the latter part of the series which
compared favourably with 36% seen in the earlier cohort
[36]. Interestingly, it was also shown that signiﬁcantly more
patients in the latter group were found to have HCCs at
an earlier stage, and many were detected at a subclinical
stage. This was clearly a result of emerging surveillance
programmes. Recently, median survival rates of 75 months
and 5-year survival rates of 64% to 70% have been reported
which compare favourably with results with LT [37, 38].
Latest series from the far east have demonstrated a very high
5-yearsurvivalrate of79–81% inpatients withearlyHCCup
to 5cm although the majority of patients in this series had
favourable background factors [39, 40]. However, even in
expertcentres,resultsaresigniﬁcantlyworseforlargerHCCs,
especially those exceeding Milan criteria [41]. Once again, it
hastobeacknowledgedthatthesearedatafromhigh-volume
centres in a select group of patients and may not reﬂect
the overall picture. Despite these excellent results, recurrence
rates at 5 years, even after curative resections, remain
disappointingly high at nearly 80% with early recurrence
observed in nearly a third of patients [37, 42]. Rates of
early and cancer-related deaths are relatively high at 8–
10%, particularly for extended resections [43]. Outcomes
are particularly poor in resection performed for advanced
HCC with multinodular or microvascular involvement [44].
Table 3 summarises results seen with resection for HCCs
andclearlydemonstratessigniﬁcantimprovementinsurvival
ﬁgures over the last 10 years.
3.2.2. Factors Determining Outcome after Resection for HCC.
With background liver disease remaining untreated, post-
operative morbidity and noncancer mortality are related to
the extent of liver dysfunction, presence of signiﬁcant portal
hypertension, and intraoperative factors such as blood loss.
Anattemptmustbemadetospareasmuchliverparenchyma
as possible.
Speciﬁc tumour-related factors have been analysed by
many authors in an attempt to prognosticate outcome and
also to streamline patient selection. Multiple tumours, vas-
cular invasion, preoperative serum alpha-fetoprotein levels,
and tumour size are independent predictors of outcome
[37]. Similar factors along with extent of mitoses were
demonstrated to signiﬁcantly determine outcome in a mul-
ticentre study [45]. This study also demonstrated a highInternational Journal of Hepatology 5
Table 3: Improving results of liver resection for HCC.
Author Year Number of patients Inclusion criteria
if any
3-year
survival (%)
5-year
survival (%)
Iwatsuki and Starzl [35] 1988 55 None 25
Poon et al. [36] 2001 136a
241b None 47
62
36
49
Shi et al. [46] 2007 169 Solitary HCCc 79 61
Ishii et al. [38] 2008 162 Milan 89 70
Yamakado et al. [40] 2008 62 Milan 93 81
Canter et al. [41] 2010 94 Exceeding
Milan 66
Huang et al. [63] 2010 115 Milan 92 76
Hung et al. [39] 2011 229 Milan 79.3
aResections performed between 1989 and 1994.
bResections performed between 1994 and 1999.
cMajority within Milan criteria.
1-year mortality of 22%, the majority of them dying of
cancer recurrence or liver failure. In solitary HCCs, where
parenchymal sparing is not necessarily a problem, a wide
surgical resection margin of 2cm is associated with lower
r a t e so fr e c u r r e n c ea n db e t t e ro u t c o m e s[ 46]. There is also
some recent evidence that patients undergoing resection
for small HCCs associated with cirrhosis due to HBV have
better long-term survival than those with HCV [47]. This
is relevant whilst interpreting and comparing data from
diﬀering geographical areas since it is evident that the
majority of patients in the far east have cirrhosis related
to HBV infection whereas the commonest aetiology in the
western world is HCV. Large multifocal HCCs with vascular
involvement should be considered as contraindications for
major liver resections as should association of three or more
of the other risk factors [37, 44]. Thus, although there are no
currentrestrictionsontheupperlimitofsizeofHCCsuitable
for resection, it is clear from these data that best results are,
onceagain,obtainedinsolitaryorsmallHCCsconﬁrmingto
Milan criteria.
3.2.3. Preoperative Portal Vein Embolisation (PVE) for Major
Resections for HCC. Portal vein embolisation is a well-
established method to increase the volume and function of
the future liver remnant (FLR) prior to major liver resection
for any pathology. The number of patients that undergo
hypertrophy after PVE and the extent of that hypertrophy is
less in livers with chronic liver disease compared to that seen
in normal livers [48]. A large meta-analysis has conﬁrmed
the safety and eﬃcacy of PVE with low morbidity and ability
to perform major resections with very low mortality [49].
Another study has demonstrated better immediate outcomes
in liver resections performed for HCC with PVE than
without [50]. Unlike normal livers, the FLR necessary for
cirrhotic livers is purported to be up to 40% even in presence
of preserved liver function [51]. Recently, PVE has also been
used in combination with transarterial chemoembolisation
(TACE) to demonstrate better hypertrophy, postoperative
outcomes, and recurrence-free survival compared to PVE
alone, although no prospective randomised trials exist [52].
Thus, on the current evidence, PVE is safe and eﬃcacious
and should be regularly used to enable major curative
resections for HCC.
3.2.4. Resection or Transplantation for HCC?
With comparable results achievable with either LT or resec-
tioninselectpatientgroups,therehasbeenavigorousdebate
in terms of the best possible curative option for HCC. The
pros and cons of both modalities have already been outlined
in this paper. It is clear that best results are achieved in small
HCCs, typically within Milan criteria, with excellent liver
function and no associated comorbidities. More recently,
comparable results were demonstrated between heteroge-
neous groups of patients undergoing LT or resection for
HCCs beyond Milan criteria although the median followup
was only 34 months and signiﬁcantly more patients in the
LT group had established cirrhosis [41]. Outcomes have to
be based on an intention-to-treat basis, taking into account
waiting times, dropouts, and waiting-list mortality. It would
be impossible to perform a prospective randomised trial
to establish the best modality of treatment. Although LT
addresses the issue of liver disease, recurrence for certain
conditions such as the viral hepatides is common. These
patients also have to be on life-long immunosuppression
which is unnecessary after a liver resection.
A recent consensus conference concluded that LT is
the preferred method for patients with cirrhosis and HCC
meeting Milan criteria while resection with wide margins is
the treatment of choice for selected patients with cirrhosis
that have well-preserved liver function, with no portal
hypertension without a size restriction [53]. The Barcelona
grouphavealsoproposedanalgorithmbasedontheirstaging
system and suggest that resection should be used for very
early single HCCs (<2cm) with normal liver function and
no portal hypertension whereas all other patients within
Milan criteria and suitable for curative treatment should be
considered for LT [8]. The APASL guidelines recommend
liver resection as a ﬁrst-line curative treatment of solitary or
multifocal HCC conﬁned to the liver, which are anatomically6 International Journal of Hepatology
Table 4: Results for RFA for HCC.
Author Year Number of patients Inclusion criteria if any 3-year survival (%) 5-year survival (%)
Chen et al. [58] 2006 71 Solitary <5cm 71 68 a
Livraghi et al. [59] 2008 218 Solitary <2cm 76 55 b
N’Kontchou et al. [60] 2009 222 Up to 3 HCC <5cm 40 c
Peng et al. [62] 2010 224 Solitary <5cm 60
Huang et al. [63] 2010 115 Milan 70 55
a4-year survival.
bSurvival increased to 69% for “operable” patients.
cSurvival increased to 76% for “operable” patients.
resectable and where there is satisfactory liver function
reserve. LT should preferably be used for HCCs within Milan
criteria in patients with more advanced liver disease (Child
P u g hBo rC )i fm e d i c a l l yﬁ t[ 9]. The NCCN guidelines are
similar but more ambiguous about the optimal size of HCC
best suited for resection. LT is reserved for patients within
Milan criteria and more advanced liver disease and poten-
tially for those that are “unresectable” due to unfavourable
tumourlocationorinadequateliverreserve[10].Thisreﬂects
theincreasinguseofresectionastheﬁrstlineofmanagement
for early HCC and may, in part, be also due to the fact that
UNOS criteria specify that patients eligible for LT should
not be considered for resection. Thus, although there are
certain diﬀerences in all these guidelines, it is clear that use
of surgical resection as the ﬁrst treatment for small HCCs in
a well-preserved liver is increasingly prevalent. This is clearly
helped by the fact that although long-term results after LT
have remained relatively static over the last 10 years, those
with resection have signiﬁcantly improved.
3.3. Ablative Techniques for HCC. Ablative techniques have
an established role in the management of HCC. Radiofre-
quency ablation (RFA) is the most commonly used ablative
technique for HCC. Other modalities include percutaneous
ethanol injection (PEI) and microwave ablation (MWA).
RFAisaminimallyinvasiveprocedurethatcanbeperformed
percutaneously or operatively using both an open and a
laparoscopic approach, with relatively low major complica-
tion rates. It can also be performed in patients who would
be unsuitable for surgery (either LT or resection) due to
associated comorbidity. It, however, is the only potentially
curative technique that does not permit histological analysis
of the tumour, and hence tumour-based prognostic criteria
for best outcomes cannot be readily determined. In terms
of safety and eﬃcacy, a large meta-analysis in 2001 demon-
strated an overall mortality of 0.5% and a complication rate
of 8.9% [54]. More recent studies have demonstrated further
lowering of mortality (0.1%) and complication rates [55].
The commonest complications are liver abscesses, biliomas,
haemorrhage, and so forth. Although both RFA and PEI are
eﬀective techniques, studies have demonstrated that necrotic
eﬀect of RFA is more predictable for larger tumour sizes and
that RFA is superior in terms of local tumour progression
and disease-free survival [56].
3.3.1. Results of RFA for HCC. RFA is best used for tumours
less than 3cm after which the incidence of local recurrence
increases. Vascular proximity leads to a heat-sink eﬀect
minimising the eﬃcacy of the burn and thereby promoting
higher recurrence rates. Signiﬁcantly better results seem to
be obtained when the procedure is performed operatively
ratherthanpercutaneously[57].Arandomisedtrialreported
comparable outcomes between RFA and surgical resection
for solitary small HCCs <5cm with 4-year survival rates
between 64 and 68% [58]. Another more recent study
demonstrated sustained complete response rate for RFA for
very small HCCs to be over 97% with a 5-year survival of
69% in tumours that would be considered operable [59].
This was improved upon in another series reporting a 5-
year survival rate of 76% for patients considered operable
disease by BCLC criteria [60]. A large retrospective study
demonstrated that in Child Pugh A cirrhotics, RFA and
resection oﬀered equivalent beneﬁts for tumours less than
3cm while resection provided better survival when the HCC
was larger than 3cm but still within Milan criteria [61].
A Chinese study demonstrated 5- and 7-year survival of
60% and 55% with RFA as the primary treatment for HCCs
within Milan criteria [62]. The latest randomised controlled
trial comparing RFA and resection for HCCs within Milan
criteria demonstrated that overall survival and recurrence-
free survival were signiﬁcantly better with curative resection
ratherthanRFA[63].Inthisstudy,theoverall5-yearsurvival
rates were 55% with RFA and 76% with resection, both
comparing favourably with LT. Most of these series enrolled
patients with Child Pugh score A and tumours either within
Milan criteria or small solitary tumours <5cm. Table 4
summarises results of RFA for HCCs.
ThesedatawouldsuggestthatRFAisprobablyaseﬀective
as both resection and LT for small HCCs in early cirrhotic
patients with preserved liver function. However, more
p r o s p e c t i v er a n d o m i s e dt r i a l sw i t hm u c hl a r g e rn u m b e ro f
patients would be necessary to demonstrate the superior
treatment modality. Recent trials have demonstrated slight
inferiority of RFA over resection for small HCCs. The BCLC
algorithm recommends RFA as the primary treatment for
single small HCCs in patients that are high risk for operative
management due to associated comorbidity [8]. Similar
approach is advocated by both APASL and the NCCN
which recommend RFA as an equivalent alternative forInternational Journal of Hepatology 7
any HCC considered suitable for resection, namely, solitary
HCC <3cm in a patient with Child Pugh A cirrhosis. This
approach may yet change as more data on randomised trials
between RFA and resection becomes available.
M o r er e c e n t l y ,o t h e ra b l a t i v et e c h n i q u e ss u c ha sM W A
and high-intensity focussed ultrasound (HIFU) have been
used in an attempt to overcome some of the limitations of
RFA. These and others such as electroporation need to be
further evaluated in clinical trials [64].
3.3.2. RFA as a Bridge or a Holding Therapy to Transplanta-
tion. Longer waiting times for LT and rising dropout rates
prompted the evaluation of RFA and TACE as holding tech-
niques for patients who would otherwise progress beyond
Milan criteria and also for downstaging patients with HCCs
already beyond Milan criteria to make them eligible for
LT [65]. Such early feasibility studies indicated that some
tumours could be successfully downstaged. However, it is
doubtful whether downstaging larger tumours with RFA
or TACE alters prognosis or biological behaviour of the
tumour. A study which applied this practice demonstrated
overall 5-year survival less than 50% [66]. In fact, nearly
half of all patients “dropped out,” and the survival on an
intention-to-treat basis was less than 25%. It is assumed
that nonresponders are a self-selecting group of patients
that manifest unfavourable tumour biology. Much better
outcomes were demonstrated recently with a dropout rate of
30% and an intention-to-treat 4-year survival of 69% [67].
TheroleofRFAandTACEasholdingtherapyforpatients
satisfying organ allocation criteria is equally contentious. It
could be employed to minimise dropout rates, a natural
occurrence on waiting lists. However, it does not confer
additional beneﬁts or improve survival after successful LT
[68]. Once again, large randomised trials are necessary
to conclusively demonstrate beneﬁt but are probably not
feasible.
4. Conclusions
HCC is a common but complex multifactorial condition
with poor outcomes worldwide. Few patients ever come to
curative surgical therapy. The role of surgical techniques
has gradually expanded over the years with signiﬁcant
improvement in outcomes with liver resection whilst those
with LT have remained static. Outcome after any curative
treatment for HCC is related not only to the stage of the
tumourbutalsototumourbiology,backgroundliverdisease,
and associated comorbidities.
Staging algorithms such as those proposed by the
BCLC, APASL, and the NCCN provide useful, evidence-
based guidance towards decision-making. Treatment should
be individualised, preferably in high-volume centres of
expertise with facilities for both liver resection and liver
transplantation.
For small solitary HCCs <2-3cm and normal liver
function, LT, resection and RFA seem to confer comparable
beneﬁtalthoughrecenttrialsconﬁrmsuperiorityofresection
compared to RFA. Milan criteria continue to be utilised
by most transplant programs, and although there seems
to be a case for modest increase, the results have not
been replicated across national programs. LT should be the
preferred approach for patients with larger tumours within
Milan criteria especially with advanced liver dysfunction.
Resection should be preferred either for very small HCCs
or for those that have exceeded Milan criteria but still have
excellent liver function and no portal hypertension. RFA
should be the preferred method of ablation and should
be utilised for small HCCs not otherwise ﬁt for surgical
management.
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